However, human clinical trials targeting CCR2, CCR5, CCL2, and CXCL8 by small molecules or monoclonal antibodies have failed to demonstrate clinical efficacy in RA (reviewed in [4]). This evidence concerns the gene CCR2 and rheumatoid arthritis.